Table 3.
|
DURATION-1 |
DURATION-5 |
DURATION-2 |
DURATION-3 |
|||||
---|---|---|---|---|---|---|---|---|---|
ExQW | ExBID | ExQW | ExBID | ExQW | Sitagliptin | Pioglitazone | ExQW | Glargine | |
Nausea (%) | 26 | 35 | 14 | 35 | 24 | 10 | 5 | 13 | 1 |
Vomiting (%) | 11 | 19 | 5 | 9 | 11 | 2 | 3 | 4 | 1 |
Diarrhea (%) | 14 | 13 | 9 | 4 | 18 | 10 | 7 | 9 | 4 |
Injection site reactions (%) | 30 | 15 | 13 | 10 | 10 | 7 (PBO) | 13 | 2 | |
Minor hypoglycemia (%) | 5 | 6 | 4 | 3 | 1 | 3 | 1 | 8 | 26 |
The only adverse events not included here that occurred with an incidence ≥10% in any of these DURATION trials were as follows: with exenatide once weekly (ExQW), nasopharyngitis (13% DURATION-3), headache (10% DURATION-3), urinary tract infection (10% DURATION-1), and constipation (10% DURATION-1); with exenatide twice daily (ExBID), upper respiratory tract infection (17% DURATION-1); with pioglitazone, upper respiratory tract infection (10% DURATION-2); and with insulin glargine, nasopharyngitis (17% DURATION-3).
PBO, placebo microsphere injection (combined for sitagliptin and pioglitazone groups).